Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions

Journal of Invasive Cardiology

Volumn 17, Issue 10, 2005, Pages 518-520

  Ahmad, Mayraj ^a   Schwalm, Jon David ^a   Velianou, James L ^a   Natarajan, Madhu K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; STANDARD; TEACHING HOSPITAL; URBAN AREA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL PROTOCOLS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PATIENT DISCHARGE; POSTOPERATIVE CARE; PRACTICE GUIDELINES; PROSPECTIVE STUDIES;

EID: 33645969926     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators (CARE). N Engl J Med 1996;335:1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. N Engl J Med 1998;339:1349-1357.
4. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized controlled trial. Lancet 2002;360:7-22.
5. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. Lescol Intervention Prevention Study (LIPS): A randomized controlled trial. JAMA 2002;287:3215-3222.
6. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696.
7. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE-IT). N Engl J Med 2004;350:1495-1504.
8. Fonarow GC, French WJ, Parsons LS, et al. for the National Registry of Myocardial Infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
9. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of under treatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307.
10. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-567.
11. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J 2001;22:554-572.
12. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. JAMA 2001;285:1711-1718.
13. Fonorow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol 2001;87:819-822.
14. Smith SCJ, Blair SN, Bono RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001;104:1577-1579.
15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002;106:1893-1900.
16. Adult Treatment Panel III: Executive summary of the third report on the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285:2486-2497.
17. Genest J, Frohlich J, Fodor G, McPherson R. Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the Canadian 2003 update. Can Med Assoc J 2003;169:921-924.
18. Steg, P, Goldberg, R, Gore, J, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358.